Compare CRTO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | FDMT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.5M | 695.3M |
| IPO Year | 2013 | 2019 |
| Metric | CRTO | FDMT |
|---|---|---|
| Price | $18.08 | $12.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $18.85 | ★ $28.09 |
| AVG Volume (30 Days) | 383.3K | ★ 957.9K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | 18.79 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $2,296,692,000.00 | $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.43 | $51.94 |
| P/E Ratio | $35.57 | ★ N/A |
| Revenue Growth | 27.65 | ★ 230194.60 |
| 52 Week Low | $13.95 | $6.96 |
| 52 Week High | $25.29 | $16.93 |
| Indicator | CRTO | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 72.12 | 48.62 |
| Support Level | $16.42 | $8.68 |
| Resistance Level | $18.66 | $13.64 |
| Average True Range (ATR) | 0.81 | 0.94 |
| MACD | 0.40 | 0.11 |
| Stochastic Oscillator | 95.36 | 56.17 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).